Open AccessTransplantation of hematopoietic stem cells from the peripheral blood
Author(s) -
Jansen Jan,
Hanks Susan,
Thompson James M.,
Dugan Michael J.,
Akard Luke P.
Publication year - 2005
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/j.1582-4934.2005.tb00335.x
Subject(s) - peripheral blood stem cells , haematopoiesis , stem cell , peripheral blood , hematopoietic stem cell transplantation , transplantation , immunology , biology , medicine , microbiology and biotechnology
Hematopoietic stem cells can be collected from the peripheral blood. These hematopoietic stem cells (HSC), or better progenitor cells, are mostly expressed as the percentage of cells than react with CD34 antibodies or that form colonies in semi‐solid medium (CFU‐GM). Under steady‐state conditions the number of HSC is much lower in peripheral blood than in bone marrow. Mobilization with chemotherapy and/or growth factors may lead to a concentration of HSC in the peripheral blood that equals or exceeds the concentration in bone marrow. Transplantation of HSC from the peripheral blood results in faster hematologic recovery than HSC from bone marrow. This decreases the risk of infection and the need for blood‐product support. For autologous stem‐cell transplantation (SCT), the use of peripheral blood cells has completely replaced the use of bone marrow. For allogeneic SCT, on the other hand, the situation is more complex. Since peripheral blood contains more T‐lymphocytes than bone marow, the use of HSC from the peripheral blood increases the risk of graft‐versus‐host disease after allogeneic SCT. For patients with goodrisk leukemia, bone marrow is still preferred, but for patients with high‐risk disease, peripheral blood SCT has become the therapy of choice.